To elucidate the role of HLA‐I molecules in increased NK resistance in cancer cells, we knocked out β2 microglobulin (B2M) in MB231 and MCF7 cells using the CRISPR‐Cas9 technology (Figure S3D, Supporting Information). The gene discussed is B2M; the disease is cancer.